re: bioshares - buy
Techi is of course quite correct to claim that antisense is a proven technology. Keep in mind that antisense has roughly a 10 year headstart over competing technologies such as RNAi and siRNA.
ANP shareholders might also note that Avi Biopharma recently released positve pre-clinical studies on a new antisense compound targeting dengue virus (see below).
As I see it, the FDA hesitation re Genta's melanoma compound, while significant for Genta, is only a minor set back for ANP, and the recent fall in ANP's SP is an over-reaction to Genta.
ANP's SP will be a function of news flow over the next 12 months, and the balance of probabilities strongly points towards positive news in the short to medium term.
For those out of the loop, I recommend Scott Power's (ABN Amro) May 10 report on ANP which can be downloaded form ANP's website. Incidentally, I recently spoke with Power and he maintains his buy recommendation and 29c price target.
AVI BioPharma's NEUGENE Antisense Shows Inhibition of Dengue Virus
01-Jun-04 / 05:40 AM Back to News Room
PORTLAND, Ore.--(BUSINESS WIRE)--June 1, 2004--AVI BioPharma, Inc. (Nasdaq:AVII - News) presented results of a study showing inhibition of dengue virus with its NEUGENE® antisense compounds at the Seventh International Symposium on Positive-Strand RNA Viruses held in San Francisco May 27-June 1. Dengue virus is a single-stranded RNA virus that is endemic in most tropical countries of the South Pacific, Asia, the Caribbean, the Americas and Africa.
"This presentation describes how AVI's NEUGENE antisense compounds specifically block dengue viral replication in cell culture," said Patrick L. Iversen, Ph.D., senior vice president of research and development at AVI. "These results suggest that our NEUGENE antisense compound has therapeutic potential for the control of dengue virus infections."
The study, conducted in cooperation with the Centers for Disease Control and Prevention (CDC), evaluated the ability of AVI's NEUGENE compounds to inhibit replication of dengue virus strains 1 through 4. Dengue virus is a member of the flavivirus (Flaviviridae) family, which includes hepatitis C virus (HCV), yellow fever virus and West Nile virus, as well as a number of viruses associated with bioterrorism. The presentation was made by David Stein, a principal scientist at AVI BioPharma.
"Outbreaks of dengue virus represent a major global public health problem, especially in certain subtropical and tropical locations," said Peter O'Hanley, Ph.D., M.D., M.P.H., senior vice president of clinical development and regulatory affairs at AVI. "There is an urgent need to test worthwhile novel preventative and therapeutic agents to control dengue since there are no approved drugs or vaccines for this infection or disease. These new scientific findings about dengue-targeted NEUGENE compounds foster interest to test them in a number of clinical settings, including in military personnel deployed in hyperendemic dengue locales and in indigenous populations residing in hyperendemic dengue locales."
The presentation, titled "Inhibition of Dengue Virus Serotypes 1-4 in Cell Culture with Morpholino Oligomers," describes research evaluating the inhibition of multiple dengue strains using several NEUGENE compounds in cell culture. This study tested five NEUGENE strategies to evaluate which compounds are both specific and efficacious against multiple dengue viral isolates. The best NEUGENE antisense compounds were highly effective against viral infection in cultured cells and were found to inhibit viral titer by up to one-millionfold. The dengue-targeted NEUGENE compounds did not inhibit West Nile viral infection of cells in culture, serving as a control for the specificity of the NEUGENE compounds.
About Dengue Virus
According to the CDC, dengue fever and dengue hemorrhagic fever (DHF) are viral diseases transmitted by mosquitoes. Dengue is the most rapidly expanding disease in most tropical and subtropical areas of the world. An estimated 50 million to 100 million cases of dengue fever occur each year, 200,000 to 500,000 of which are DHF. The disease is caused by one of four dengue virus strains. Epidemics caused by all four virus strains have become progressively more frequent and larger in the past 20 years. After an incubation period of from three to 14 days, dengue fever is characterized by a sudden onset of high fever, severe frontal headache, and joint and muscle pain. Many patients also experience nausea, vomiting and a rash. The strain of the infecting virus, as well as the age, immune status and genetic predisposition of the patient can all affect whether a person develops general dengue fever or the far more severe and life-threatening DHF. More information about dengue can be found at the CDC Web site, http://www.cdc.gov/ncidod/dvbid/dengue/index.htm.
About AVI BioPharma
AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: third-generation NEUGENE antisense drugs and cancer immunotherapy. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to target single-stranded RNA viruses, including West Nile virus, SARS coronavirus, calicivirus and hepatitis C. AVI's second technology, AVICINE®, is a therapeutic cancer vaccine with late-stage trials planned for the treatment of pancreatic cancer. More information about AVI is available on the company's Web site at http://www.avibio.com/.
ANP Price at posting:
0.0¢ Sentiment: LT Buy Disclosure: Not Held
